FDA Approves Fruzaqla in Refractory Metastatic Colorectal Cancer

The FDA approved fruquintinib (Fruzaqla, Takeda ) for adults with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy; an anti–vascular endothelial growth factor (anti-VEGF) therapy; and, if RAS wild-type and medically appropriate, an anti–epidermal growth factor receptor (anti-EGFR) therapy.

Efficacy was evaluated in FRESCO-2 and FRESCO. FRESCO-2, an international, multicenter, randomized, double-blind,